Aptus Capital Advisors LLC Reduces Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aptus Capital Advisors LLC significantly reduced its holdings in Thermo Fisher Scientific by 79.8%, now owning 8,671 shares worth approximately $4.3 million.
• Thermo Fisher recently announced a quarterly dividend of $0.43 per share, with an annualized yield of 0.3% and a dividend payout ratio of 9.95%.
• The company's latest quarterly earnings outperformed expectations, reporting $5.36 EPS and $10.86 billion in revenue, which was higher than analysts' estimates.

Aptus Capital Advisors LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 79.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,671 shares of the medical research company's stock after selling 34,309 shares during the period. Aptus Capital Advisors LLC's holdings in Thermo Fisher Scientific were worth $4,315,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $25,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $31,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, Navigoe LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $37,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TMO shares. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. HSBC reiterated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Stock Up 3.4%

Shares of NYSE TMO traded up $16.4780 during trading hours on Friday, hitting $500.2380. 1,778,365 shares of the stock were exchanged, compared to its average volume of 2,406,376. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $188.89 billion, a PE ratio of 28.93, a PEG ratio of 2.58 and a beta of 0.74. The firm has a fifty day moving average price of $443.02 and a 200-day moving average price of $457.46. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $52,037,916.68. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,896 shares of company stock worth $8,593,838 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.